Carnegie Investment Counsel Trims Position in Hims & Hers Health, Inc. $HIMS

Carnegie Investment Counsel lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 47.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 242,349 shares of the company’s stock after selling 217,925 shares during the period. Carnegie Investment Counsel owned approximately 0.11% of Hims & Hers Health worth $12,081,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of HIMS. Signaturefd LLC increased its position in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after acquiring an additional 388 shares in the last quarter. Lake Hills Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter worth $277,000. Occidental Asset Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter worth $305,000. Dakota Wealth Management acquired a new stake in shares of Hims & Hers Health in the second quarter worth $354,000. Finally, Fiduciary Alliance LLC increased its position in shares of Hims & Hers Health by 120.4% in the second quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company’s stock worth $5,446,000 after acquiring an additional 59,686 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $48.51 on Friday. The firm has a market cap of $10.96 billion, a P/E ratio of 60.63, a P/E/G ratio of 3.29 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a 1-year low of $18.33 and a 1-year high of $72.98. The firm has a fifty day moving average of $51.08 and a two-hundred day moving average of $49.34.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares in the company, valued at approximately $9,105,385.20. This trade represents a 26.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the completion of the transaction, the insider owned 297,139 shares in the company, valued at approximately $15,005,519.50. The trade was a 4.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,432,206 shares of company stock valued at $74,248,448. Corporate insiders own 13.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.